Je was op zoek naar: anticoagulation (Engels - Deens)

anticoagulation
antikoagulation

therapeutic anticoagulation
terapeutisk antikoagulation

indication for anticoagulation
indikation for antikoagulation

use of concomitant anticoagulation
brug af samtidig antikoagulation

coumarin-derivative anticoagulation
antikoagulantia af coumarintypen

suitable anticoagulation tests is
passende antikoagulations-test

- medicines for anticoagulation (warfarin),
- blodfortyndende medicin (warfarin),

close monitoring of anticoagulation levels is
tæt monitorering af antikoagulationsniveauer er nødvendig.

close monitoring of anticoagulation levels is warranted.
tæt monitorering af antikoagulationsniveauer er nødvendig.

excessive anticoagulation may require interruption of pradaxa treatment.
overdreven antikoagulation kan kræve afbrydelse af pradaxa-behandling.

the concomitant use of heparin anticoagulation may contribute to bleeding.
samtidig behandling med heparin kan bidrage til blødning.

risk of supratherapeutic or subtherapeutic anticoagulation with coumarin based anticoagulants
risiko for superterapeutisk eller subterapeutisk antikoagulation med kumarinbaserede antikoagulantia

recommendations for use in patients scheduled for a switch to oral anticoagulation
koagulationsanormaliteter, som muligvis forhindrer en passende appt respons.

anticoagulation in adult patients with hit type ii and thromboembolic disease:
antikoagulationsbehandling af patienter med type ii hit og thromboembolisk sygdom:

patients of advanced age have an increased risk of bleeding complications with anticoagulation.
-pædiatrisk brug:sikkerheden og effektiviteten til behandling af pædiatriske patienter er ikke

did not influence the anticoagulation monitoring (inr) activity of warfarin. ed
fondaparinux farmakokinetik.i interaktionsstudier udviste en dosis på 10 mg fondaparinux ingen indflydelse på antikoagulationskontrol med warfarin målt som inr-aktivitet. et

the patient should continue anticoagulation therapy during the course of thalidomide treatment.
patienten skal fortsætte med den antikoagulerende behandling under thalidomidbehandlingen.

in clinical studies bivalirudin has been shown to provide adequate anticoagulation during pci procedures.
i kliniske undersøgelser har bivalirudin vist sig at give tilstrækkelig antikoagulation under pci- procedurer.

elderly: patients of advanced age have an increased risk of bleeding complications with anticoagulation.
Ældre: patienter af en høj alder har en forøgede risiko for blødningskomplikationer med anti- koagulation.

for atrial fibrillation lasting longer than 48 hours, anticoagulation was required as per treatment guidelines.
til atrieflimren med varighed over 48 timer var antikoagulering påkrævet i henhold til behandlingsvejledningerne.